Takeda’s off-the-shelf stem cell therapy approved in Europe

By Dan Stanton

- Last updated on GMT

Alofisel (darvadstrocel) has become the first allogeneic stem cell product to be approved in Europe.

On Friday, the European Commission (EC) granted approval of Takeda’s Alofisel – previously known as Cx601 – for the treatment of complex perianal fistulas in adult patients with Crohn's disease, making it the first allogeneic stem cell therapy to receive central marketing authorization (MA) approval in Europe.

While autologous therapies are made using a patient’s own cells within a timely and specialised supply chain, allogeneic – or ‘off-the-shelf’ – cell products can be manufactured more in line with standard biotherapeutics, with consistent pharmaceutical release criteria, over time and from batch to batch.

Alofisel is made in plastic flasks in incubators at a one-litre scale, using stem cells taken from healthy volunteers who have undergone liposuction for cosmetic reasons at a facility in Madrid, Spain run by TiGenix.

TiGenix partnered with Japanese firm Takeda Pharmaceuticals in July 2016 for the development and commercialisation of the product.

Earlier this year,​ Takeda launched a voluntary conditional takeover bid for TiGenix valued at €520m ($647m). The deal has not yet been completed, and as such Takeda will pay TiGenix €15m for the successful approval of Alofisel.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers

Follow us


View more